BioProcess Insider - News BioProcess International

COVID-19 to shape mRNA vaccine and therapeutic sector for years to come

COVID-19 established mRNA vaccines as an effective therapeutic option and – says a technology expert – has set the blueprint for how they will be made for the foreseeable future. Developers were working on mRNA-based medicines before 2020 with Alnylam’s polyneuropathy treatment Onpattro (pa ...

BioMagnetic Solutions to build multi-million-dollar Pennsylvania plant
BioMagnetic Solutions will build a ferrofluid and monoclonal antibody production facility at Innovation Park in Pennsylvania, US. Gamma Bio ...
Switzerland flexing its CGT muscle with a little help from Novartis and Roche
Heavy investment in R&D and manufacturing capabilities is driving the Swiss advanced therapy space but challenges including the skill-deficit ...
Scaling-up AAV production? Take your time to develop best processes
The lack of standardization surrounding gene therapy production means process design can be more important than speed to clinic, says Oxford BioM ...
CureVac reallocating failed COVID vax capacity to support next-gen mRNA
Having abandoned its COVID-19 candidate CVnCoV, CureVac has switched up its manufacturing network in preparation for a second-generation messenge ...